Trials / Withdrawn
WithdrawnNCT04054973
L-arginine Study for Persistent Symptoms of Schizophrenia
An Open-label Feasibility Trial of Adjunctive L-arginine and Tetrahydrobiopterin Combination in Patients With Treatment Resistant Schizophrenia
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Massachusetts, Worcester · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to see if daily combination treatment of L-arginine and Kuvan changes brain chemistry in people experiencing schizophrenia as measured by MRS brain scans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | L-arginine | 6000mg of L-arginine daily for 14 days |
| DRUG | Sapropterin Dihydrochloride | 800mg of Kuvan daily for 14 days |
Timeline
- Start date
- 2019-09-11
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2019-08-13
- Last updated
- 2022-01-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04054973. Inclusion in this directory is not an endorsement.